Comparative Pharmacology
Head-to-head clinical analysis: TARACTAN versus THIOTHIXENE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TARACTAN versus THIOTHIXENE HYDROCHLORIDE.
TARACTAN vs THIOTHIXENE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thioxanthene antipsychotic; blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic system; also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Thiothixene hydrochloride is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the central nervous system (CNS), particularly in the mesolimbic and mesocortical pathways. It also has alpha-adrenergic blocking activity and weak anticholinergic effects.
Oral: 25-50 mg three times daily, increased as needed to 400-600 mg/day. IM: 12.5-25 mg every 6-8 hours.
Initial: 2-5 mg orally 3 times daily; maintenance: 15-30 mg orally per day in divided doses; maximum: 60 mg orally per day.
None Documented
None Documented
Terminal elimination half-life is approximately 20-40 hours (mean 30 hours). Steady-state reached in 5-7 days.
Terminal elimination half-life: 34 hours (range 25–50 hrs) in adults; clinical context: allows once-daily dosing.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Metabolites eliminated renally (30%) and fecally (70%).
Renal: primarily as metabolites, <1% unchanged; fecal: minor; biliary: some metabolites excreted in bile.
Category C
Category C
Typical Antipsychotic
Typical Antipsychotic